Antares Pharma, Inc.

Published Date: 14/06/2011
Category: Drug Delivery & Devices

Research Report Decription

Antares Pharma, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features: 

• Detailed information on Antares Pharma, Inc. required for business and competitor intelligence needs
•  A study of the major internal and external factors affecting Antares Pharma, Inc. in the form of a SWOT analysis 
• An in-depth view of the business model of Antares Pharma, Inc. including a breakdown and examination of key business segments 
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Antares Pharma, Inc. 
• Intelligence on Antares Pharma, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Antares Pharma, Inc., such as business expansion, restructuring, and contract wins 
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Antares Pharma, Inc. and the factors that influence its strategies
• Track strategic initiatives of the company and latest corporate news and actions
• Assess Antares Pharma, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Antares Pharma, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Antares Pharma, Inc.

Paper Highlights:

Antares Pharma is a product focused specialty pharmaceutical company engaged in the development, production and marketing of pharmaceutical delivery products, including transdermal gels, oral disintegrating tablets and reusable needle-free and disposable pressure assisted auto injector and pen injector systems. The company primarily operates in the US and Switzerland. It is headquartered in Ewing, New Jersey and employed 19 people as of March 15, 2010. The company recorded revenues of $8.3 million during the financial year (FY) ended December 2009, an increase of 46.8% over FY2008. The operating loss of the company was $9.7 million during FY2009, as compared to an operating loss of $12.2 million in FY2008. The net loss was $10.3 million in FY2009, as compared to a net loss of $12.7 million in FY2008.